
The US Preventive Task Force (USPSTF) has updated screening criteria by expanding the age range and reducing the smoking history required for eligibility; the International Lung Screen Trial (ILST) data have shown that PLCOM2012 performs better for eligibility than USPSTF criteria. Screening adherence is low and depends upon multiple systems and patient/candidate‐related factors. COVID‐19 affects lung cancer treatment and screening through delays and disruptions; specific operational challenges need to be met. Over 70% of suspected malignant lesions develop in the periphery of the lungs. Bronchoscopic navigational techniques have been steadily improving to allow greater accuracy with target lesion approximation and diagnostic yield.
Like
Save
Share